Argentiere Capital’s Gilead Sciences GILD Stock Holding History

Argentiere Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-50,000	Closed	-$3.13M	–	56
2018 Q4	$3.13M	Hold	50,000	–	–	0.98%	31
2018 Q3	$3.86M	Hold	50,000	–	–	0.39%	39
2018 Q2	$243K	Buy	+50,000	New	+$3.53M	0.09%	55
2016 Q4	–	Sell	-200,000	Closed	-$311K	–	63
2016 Q3	$311K	Hold	200,000	–	–	0.3%	42
2016 Q2	$290K	Hold	200,000	–	–	0.23%	47
2016 Q1	$506K	Buy	+200,000	New	+$18M	0.3%	45

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Argentiere Capital's GILD Position: Q1 2019 in Review

Argentiere Capital sold out of Gilead Sciences (GILD) in Q1 2019, closing a stake of 35,000 shares — an estimated $2.19M sold.

Argentiere Capital first reported a position in GILD in Q1 2016 and held it in 10 quarters. The position peaked at $8.57M in Q1 2016. 1,492 funds tracked by Wall St. Rank hold GILD as of Q1 2019.

Argentiere Capital reported no remaining Gilead Sciences position as of Q1 2019 after selling out during the quarter.
Argentiere Capital sold 35,000 Gilead Sciences shares in Q1 2019, an estimated $2.19M.
Argentiere Capital first reported a position in Gilead Sciences in Q1 2016 and held it in 10 quarters.
Argentiere Capital's Gilead Sciences position peaked at $8.57M in Q1 2016.
1,492 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2019.

Based on Argentiere Capital's 13F filing for Q1 2019, filed 15 May 2019.